Time slot's time in Taipei (GMT+8)
2025/11/21 12:10-13:00 Room 201 DEF
- Lunch Symposium-東竹藥品股份有限公司 EB Pharmaceutical
東竹藥品股份有限公司 EB Pharmaceutical
- Time
- Topic
- Speaker
- Moderator
- 2025/11/21 (Fri) 12:10-13:00
- Disturbance of the Cholinergic pathway in non-Alzheimer’s neurodegenerations
- Speaker:
Yu Aoh
(Taiwan)
- Moderator:
Shey-Lin Wu
(Taiwan)
- Yu Aoh
- MD
-
Attending physician, Division of Parkinsons' disease and movement disorders, Department of Neurology, China Medical University Hospital, Taichung, Taiwan
PhD program, Graduate Insitute of Biomedical Sciences, College of Medicine, China Medical University, Taichung, Taiwan
E-mail：aohyu@hotmail.com
Executive Summary：
Dr. Yu Aoh completed her neurology training in China Medical University Hospital and became an attending physician in the department of Neurology in China Medical Univerisity hospital. She has a keen interest in treating patients with movement disorders as well as headache disorders, and she is an active member in both Taiwan Movemen Disorder Society and Taiwan Headache Society. Dr. Aoh is presently under PHD program at graduate institute of China Medical University, focusing on high frequency focused ultrasound treatment, non-motor symptoms and especially pain in PD.
Dr. Yu Aoh completed her neurology training in China Medical University Hospital and became an attending physician in the department of Neurology in China Medical Univerisity hospital. She has a keen interest in treating patients with movement disorders as well as headache disorders, and she is an active member in both Taiwan Movemen Disorder Society and Taiwan Headache Society. Dr. Aoh is presently under PHD program at graduate institute of China Medical University, focusing on high frequency focused ultrasound treatment, non-motor symptoms and especially pain in PD.
Lecture Abstract：
Alzheimer’s disease is the most common neurodegenerative disorder, followed by Parkinson’s disease. Considering the established evidence of cholinergic deficiency in Alzheimer’s disease, anti-cholinergic esterase inhibitors had been the main medical treatment. However, in other neurodegenerative diseases, such as Parkinson’s disease, the altered cholinergic pathway also plays a role in their pathophysiology. Herein we will review the literature of cholinergic pathway involvement in non-Alzheimer’s neurodegenerations and evidence for treatment targeting this disturbed circuit.
Alzheimer’s disease is the most common neurodegenerative disorder, followed by Parkinson’s disease. Considering the established evidence of cholinergic deficiency in Alzheimer’s disease, anti-cholinergic esterase inhibitors had been the main medical treatment. However, in other neurodegenerative diseases, such as Parkinson’s disease, the altered cholinergic pathway also plays a role in their pathophysiology. Herein we will review the literature of cholinergic pathway involvement in non-Alzheimer’s neurodegenerations and evidence for treatment targeting this disturbed circuit.
